Evidence map›Paper›PMID 37668041›Full record

ReviewCancer medicine2023

Nanodelivery systems: An efficient and target-specific approach for drug-resistant cancers.

Sumel Ashique, Ashish Garg, Afzal Hussain, Arshad Farid, Prashant Kumar, Farzad Taghizadeh-Hesary

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Current Advances in Nanocarriers for Cancer Therapy.International journal of nanomedicine · 2025
    Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 4 countries.

Sumel AshiqueDepartment of Pharmaceutics, Pandaveswar School of Pharmacy, Pandaveswar, India.
Ashish GargGuru Ramdas Khalsa Institute of Science and Technology, Pharmacy, Jabalpur, India.
Afzal HussainDepartment of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Arshad FaridGomal Center of Biochemistry and Biotechnology, Gomal University, Dera Ismail Khan, Pakistan.
Prashant KumarTeerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, India.
Farzad Taghizadeh-HesaryENT and Head and Neck Research Center and Department, The Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-6195-2203
Dev Sanskriti Vishwavidyalaya · INGomal University · PKIndian Institute of Information Technology Design and Manufacturing Jabalpur · INIran University of Medical Sciences · IRKing Saud University · SATeerthanker Mahaveer University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer treatment is still a global health challenge. Nowadays, chemotherapy is widely applied for treating cancer and reducing its burden. However, its application might be in accordance with various adverse effects by exposing the healthy tissues and multidrug resistance (MDR), leading to disease relapse or metastasis. In addition, due to tumor heterogeneity and the varied pharmacokinetic features of prescribed drugs, combination therapy has only shown modestly improved results in MDR malignancies. Nanotechnology has been explored as a potential tool for cancer treatment, due to the efficiency of nanoparticles to function as a vehicle for drug delivery.

methodsWith this viewpoint, functionalized nanosystems have been investigated as a potential strategy to overcome drug resistance.

resultsThis approach aims to improve the efficacy of anticancer medicines while decreasing their associated side effects through a range of mechanisms, such as bypassing drug efflux, controlling drug release, and disrupting metabolism. This review discusses the MDR mechanisms contributing to therapeutic failure, the most cutting-edge approaches used in nanomedicine to create and assess nanocarriers, and designed nanomedicine to counteract MDR with emphasis on recent developments, their potential, and limitations.

conclusionsStudies have shown that nanoparticle-mediated drug delivery confers distinct benefits over traditional pharmaceuticals, including improved biocompatibility, stability, permeability, retention effect, and targeting capabilities.

Indexed as

Antineoplastic AgentsDrug Delivery SystemsDrug Resistance, NeoplasmNanomedicineNanoparticle Drug Delivery SystemNanoparticlesNeoplasmsAnimalsDrug Resistance, MultipleHumansAntineoplastic AgentsNanoparticle Drug Delivery Systemcancerchemotherapydrug deliverydrug resistancenanomedicine

Identifiers

PMID37668041
PMCPMC10557914
OpenAlexW4386438160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.